Boston Scientific enrolls patients for new stent

Boston Scientific, based in Natick, MA, is enrolling patients now in a trial for a new kind of drug-eluding coronary stent it calls Synergy. What makes it different from previous versions is that it is coated with a biodegradable polymer and drug formulation that will reduce reclogging more quickly than other stents. Then, it will disappear harmlessly, leaving only the metal stent in the vessel. The trial is expected to enroll 291 patients in Europe, Australia and New Zealand. Synergy is an investigational device in the United States. Boston Scientific's previous-generation Promus stent was approved in Europe late last year. Release

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.